Last reviewed · How we verify
NVX-108
At a glance
| Generic name | NVX-108 |
|---|---|
| Also known as | Dodecafluoropentane |
| Sponsor | NuvOx LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress (PHASE1)
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (PHASE2)
- NanO2 for Large Vessel Occlusion Stroke (PHASE2, PHASE3)
- A Phase Ib/II in Patients With Acute Ischemic Stroke (PHASE1)
- The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVX-108 CI brief — competitive landscape report
- NVX-108 updates RSS · CI watch RSS
- NuvOx LLC portfolio CI